Pearl Title: Thrombotic Thrombocytopenic Purpura (TTP) and Clinical Importance of ADAMTS 13 Assays

Name of Presenter: Nahla Heikal. MD,MS

Affiliation: University of Utah. ARUP reference laboratories

DOI: 10.15428/CCTC.2017.278879
Thrombotic Thrombocytopenic purpura

- Acute, rare, fatal, and diffuse disorder resulting from occlusion of small arterioles and capillaries by microthrombi
- Defined as a pentad of:
  1. Microangiopathic hemolytic anemia
  2. Severe thrombocytopenia
  3. Neurologic abnormalities
  4. Renal function impairment
  5. Fever
- Patients may not present with the full pentad
- Recent streamlined criteria include microangiopathic hemolytic anemia and thrombocytopenia to guide initiation of plasma exchange
- TTP may involve many organs, including adrenals, heart, kidney, brain, and pancreas
- Most cases are acquired idiopathic autoimmune condition
- TTP can be congenital (Upshaw-Shulman syndrome)
Differential diagnosis

- Disseminated intravascular coagulation (DIC)
- Hemolytic uremic syndrome (diarrhea positive/negative)
- Disseminated malignancy
- Autoimmune diseases
- Drugs (quinine, interferon, calcineurin inhibitors, simvastatin)
- Malignant hypertension
- Pregnancy associated with HELLP
- Infections: viral (CMV, adenovirus, herpes simplex), bacterial (meningococcus, pneumococcus), and fungal
Pathophysiology of TTP

- Accumulation of ultra large Von Willebrand Factor multimers (ULVWF)
- Bind more avidly to platelet GPIb/IX/V
- ADAMTS 13 (a disintegrin and metalloprotease with thrombospondin type 1 motif member 13) normally cleaves and process the ULVWF into smaller fragments
- In individuals with severe deficiency in ADAMTS 13(<5-10%), accumulation of ULVWF leads to platelet adhesion, aggregation, and microvascular thrombosis
ADAMTS13 Deficiency in Non-TTP Conditions

- Disorders associated with mild ADAMTS13 deficiency (>10%):
  - Uremia
  - Sepsis
  - Chronic inflammation
  - DIC
  - Pregnancy
  - Post-operatively
  - Liver disease

- Disorders rarely associated with severe ADAMTS13 deficiency (<10%):
  - Liver disease and cirrhosis
  - Severe sepsis
  - Sepsis-induced DIC
  - Disseminated malignancy
Laboratory Studies

CBC:
- Normocytic anemia
- Profound thrombocytopenia, platelet count frequently <20X10³/µL
- Reticulocyte count, RDW, and MPV are often increased

Morphologic evaluation of peripheral smear:
- Erythrocyte polychromasia and anisocytosis
- Schistocytes are a hallmark for TTP but are not specific and can be found in other thrombotic microangiopathy

Features of hemolytic anemia:
- Decreased hemoglobin
- Increased lactate dehydrogenase
- Negative coombs test

Features of renal dysfunction
- Elevated creatinine with proteinuria and hemoglobinuria

Cardiac dysfunction
- Elevated troponin T
Peripheral blood smear for patient with TTP
ADAMTS 13

Laboratory testing

• Activity
• Antigen
• Bethesda titer
• Autoantibody titer
Activity Versus Antigen Test

- **Activity tests measure the amount of functional protein**
  - Low in both quantitative or qualitative abnormalities
  - Severe deficiency supports the diagnosis for TTP
  - ADAMTS 13 activity at diagnosis is associated with:
    - Response to plasma exchange—severe deficiency more likely to respond
    - Frequency of relapse:
      - Patients with severe deficiency are more likely to relapse
      - Severe deficiency during clinical remission means relapse is more likely
    - Overall survival
      - Patients with severe ADAMTS13 deficiency have better overall survival

- **Antigen tests measure the amount of protein, but not the protein function**
  - Antigen testing is not usually performed
  - These tests are less sensitive for the diagnosis of acquired TTP since it cannot detect qualitative abnormalities
ADAMTS 13 Activity Methods

- **Fluorescence resonance energy transfer (FRET)**
  - Assays use a synthetic VWF peptide that contains the ASDAMTS13 cleavage site
  - Contains fluorescent tag and a quencher that suppresses fluorescent emission
  - Active ADAMTS 13 from patient plasma cleaves peptide bond separating quencher from fluorescent tag, fluorescence is quantified by a fluorometer

- **ELISA method**
  - Recombinant VWF peptide containing the ADAMTS 13 cleavage site captured to a microtiter wells
  - ADAMTS 13 in patient sample cleaves the VWF fragment exposing a specific amino acid sequence
  - Labeled detection antibody detects exposed sequence and color develops using horseradish peroxidase reaction
ADAMTS 13 autoantibodies

- Differentiates acquired from inherited TTP
- Presence supports the diagnosis of acquired TTP
- Presence at diagnosis is associated with higher risk of relapse
- Persistence in clinical remission is associated with higher risk for relapse
- High titers are associated with delayed response to plasma exchange, refractory disease, and early death
- 4% of healthy individuals and 13% of patients with SLE have autoantibodies to ADAMTS 13 in the same range observed in TTP patients, despite having normal levels of ADAMTS 13
Neutralizing Versus Non-Neutralizing Antibodies

- **Neutralizing antibodies:**
  - More common ~2/3
  - Inhibit ADAMTS 13 function
  - Often called ADAMTS 13 inhibitor
  - Detected by Bethesda assay

- **Non-neutralizing antibodies:**
  - Less common ~1/3
  - Bind to ADAMTS 13 and accelerate clearance
  - Often called ADAMTS 13 antibody
  - Detected by ELISA
Bethesda Assay for ADAMTS 13 Inhibitors

- Patient Plasma
- Normal pooled plasma
- Buffer
- Patient 1:1 mix
- Control 1:1 mix
- Incubate 2h/37°C

Measure residual ADAMTS-13 activity in both mixtures and compare
Detection of Non-neutralizing antibodies

- Autoantibodies directed against ADAMTS 13 can be measured in serum or plasma samples by sandwich ELISA

- Full-length recombinant ADAMTS 13 is immobilized on the surface of an ELISA plate and binds to anti-ADAMTS 13 antibodies from the patient sample

- Bound antibodies are detected by a labeled secondary antibody that participates in a chromogenic reaction

- The ELISA autoantibodies is highly sensitive for idiopathic TTP, but less specific than the Bethesda assay
ADAMTS-13 Activity and Autoantibody Testing Algorithm

Suspected Thrombotic Microangiopathy

- Measure ADAMTS-13 activity
  - Normal
    - TTP excluded
    - Consider other TMA
  - Mild to moderate decrease
    - Unlikely idiopathic TTP
    - if clinically indicated
      - Inhibitor assay (Bethesda)
  - Marked decrease <10%

Inhibitor assay (Bethesda)

- Not Detected
  - Autoantibody assay (IgG ELISA)
    - Not detected
      - Consider ADAMTS 13 Sequencing
      - Positive—congenital TTP; Negative—requires clinical correlation
    - Low titer
      - Requires clinical correlation
    - High titer
      - Acquired TTP with Non-Neutralizing antibody

- Detected
  - Acquired TTP with Neutralizing antibody
Hereditary TTP: Upshaw-Shulman Syndrome

- Rare ~5% of TTP cases
- Occurs in infancy or childhood and may recur as chronic relapsing TTP
- Classic hallmarks are neonatal jaundice, with negative comb's test requiring blood transfusion.
- Differentiated from other causes of thrombocytopenia by ADAMTS 13 activity test <5%
- No autoantibody to ADAMTS 13
Hereditary TTP: Upshaw-Shulman Syndrome

- Autosomal recessive
- Compound heterozygous or homozygous
- Carriers have ~50% of normal activity and are asymptomatic
- ADAMTS 13 gene is located on the long arm of chromosome 9 and has 29 exons
- At least 76 mutations have been described, mutations has been found throughout the gene
- Analytical sensitivity is >99%
- Evaluating potentially affected family members, including prenatal diagnosis
- Can establish genotype-phenotype correlation
Prognosis and Treatment of acquired TTP

- Untreated TTP is associated with high mortality due to multi-organ failure
- Relapse is seen in 30-60% of patients
- Treatment must be initiated before results of lab testing are available
- Early initiation of plasma exchange with fresh frozen plasma

- Steroids
- Rituximab
- Cyclophosphamide, vincristine or cyclosporine A

- N-acetylcysteine
- Bortezomib
- Recombinant ADAMTS13
- Caplacizumab

Off-label use

New treatments under evaluation
References


7- Sadler JE. What’s new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura. *Hematology* 2015;2015:631-636


Disclosures/Potential Conflicts of Interest

Upon Pearl submission, the presenter completed the Clinical Chemistry disclosure form. Disclosures and/or potential conflicts of interest:

- **Employment or Leadership**: No disclosures
- **Consultant or Advisory Role**: No disclosures
- **Stock Ownership**: No disclosures
- **Honoraria**: No disclosures
- **Research Funding**: No disclosures
- **Expert Testimony**: No disclosures
- **Patents**: No disclosures
Thank you for participating in this Clinical Chemistry Trainee Council Pearl of Laboratory Medicine.

Find our upcoming Pearls and other Trainee Council information at www.traineecouncil.org

Download the free Clinical Chemistry app on iTunes today for additional content!

Follow us: